India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

年终总结能工巧匠，必善用其器。Lonza旗下的电穿孔核转染技术(Nucleofection)无疑是细胞转染的超强利器。电穿孔核转染是一种升级版的转染技术，它克服传统电穿孔方法在转染效率和细胞活力方面的限制。Nucleofector通过优化电场和脉冲条 ...

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b ...

Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

Celebrate advancements in bone marrow transplantation in India, offering hope and life-saving treatments for patients ...

SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...